Targeting Radiolabeled Peptides for Cancer Imaging
Sep 5, 2023
Novel Receptor-Targeting Radiolabeled Peptides for Cancer Imaging
Yubin Miao
October 11, 2012
All right, I think we are going to start.
My name is Raul Dobrak.
I'm Director of Nuclear Imaging Laboratory at Beckman
Institute and running Nuclear Imaging Laboratory.
And we don't have too many such talks about the nuclear
imaging technology.
And today we have a special guest, which is Yubin Miao.
He's an Assistant Professor in College of Pharmacy in the
University of New Mexico.
And he will be talking about the novel receptor targeting
radiolabeled peptides for cancer imaging.
So we got kind of a theme with an interest of cancer imaging.
And today we'll be talking about the radiolabeled peptides for
imaging cancer.
And just a brief biography, Dr. Miao received his PhD in
radiopharmaceutical chemistry from Beijing Normal University
and he did the postdoctoral training at the University of
Missouri, Columbia.
And right now he's the Assistant Professor working for the SPECT
PET imaging of cancer to detect with the radioactive peptides to
detect primary and metastatic tumor lesions non-invasively.
So I'm very glad to have him here.
Please direct him before the presentation.
Thank you so much for your kind introduction.
It's my great pleasure to be here and share with you our work
on novel receptor targeting radiolabeled peptides for cancer
imaging.
So in this talk I'm going to have four sections.
In the first section I'm going to give you a brief introduction
on principle of molecular imaging of cancer.
Then I'm going to give you two sets of examples.
But basically one set example will be targeting the GNI
receptor for breast cancer imaging.
Then give you two generations of the peptides targeting MC1R for
melanoma imaging.
So let me start with the principle of molecular imaging
of cancer.
So as we know to perform molecular imaging you need to
have three components, namely molecular target, imaging probe
and imaging modality here.
So both intracellular or self-surface targets can be used
as molecular targets.
Compared to the intracellular target there is an advantage
associated with the self-surface target.
That is the radiolabeled probe or imaging probe doesn't have to
penetrate the cell membrane to reach the target.
Once you determine the molecular target then you need to have
imaging probe specifically bind to the target.
And general signals for different type of imaging
modalities here.
So normally antibody, peptide or some molecules can be used as
imaging probe depending upon which imaging modality you are
going to use.
You need to label this imaging probe either with radionuclide
or SPECT PET imaging or you can label with the optical tags for
optical imaging.
So in today's talk I'm going to focus on radionuclide imaging,
basically SPECT and PET.
I think I'm going to focus on the SPECT.
So by definition SPECT means single photon emission
computer tomography and PET means positron emission tomography.
This slide shows you the peptide receptor binding specifically we
used in our project.
So basically you can see the receptors are over expressed on
the cancer cells and you can use peptide to specifically deliver
either diagnostic radionuclide or therapeutic radionuclide to bind
to the receptor for cancer imaging and treatment.
And as you can see peptide radionuclide can attach to the
peptide through a linker.
So different type of linkers can be used to optimize the binding
affinity of the molecule as well as modifying the
biodistribution properties of the molecule.
So once you inject the radiolabeled peptides in a blood stream
through the blood circulation the peptide itself can specifically
find the receptors on the cell surface and then bind there.
So you can generate, the peptide can generate signals.
Radiolabeled peptide can generate signals for SPECT and PET imaging.
This slide gives you an idea about how a radiopharmaceutical
can essentially find the targets and accumulate in the tumor
sites in the body.
So basically you need to inject a radiopharmaceutical first into
a patient through the vent.
Through the blood circulation the drug will distribute throughout
the body of the patient.
And as time goes on the drug clears from the non-tumor tissue
rapidly because there's no target available for the
radiopharmaceutical to bind.
And eventually the radiopharmaceutical remaining in the body
is retained in the tumor site because the peptide will find
the receptor and bind there.
This slide gives you an idea about the clinical imaging process.
First of all you need to inject a radiolabeled imaging probe
into a patient.
And after a certain period of time the patient will lie down
under the camera for data collection.
And the data collection can generate a lot of projections here.
And through the reconstruction process it can generate
tomograms here.
Now the radiologist will come and look at these pictures
and diagnose the disease.
So now the question is can we do this type of imaging
in a small animal?
The answer is yes.
So here I show you the nanospec CT available in our college
which can be used for the small animal imaging.
So as you can see this machine is not too big.
It's about one meter wide and 1.6 meter tall.
And we can use for mice imaging, rats, and rabbits.
I think we may be able to do small monkeys as well
by changing the size of this hole.
And here I show you two examples using the imaging probe
developed in my laboratory for the primary melanoma imaging
as well as the pulmonary metastatic melanoma imaging here.
So as you can see to generate such specific cancer images
you need to have receptor targeting or cancer specific imaging probes.
We also have a lab pet, small animal imaging pet
we can use for pet imaging.
Here I give you an example by using F18FDG into a small mouse
to detect the pulmonary metastatic melanoma imaging here.
So you can easily, through the CT image you can see the spot here
and this is a necroposy picture of the lung.
And essentially the F18FDG can detect the spot of the lung mass here.
But despite the success of F18FDG
you can see F18FDG can generate a very high background here.
The reason for that is F18FDG is not a cancer specific imaging agent.
The elevated uptake of F18FDG in cancer cells
is because cancer cells normally have higher energy consumption
compared to normal cells.
So now let me give you a couple of examples
about how to targeting the gonadotropin-releasing hormone
for breast cancer imaging.
First of all, I'd like to give you a brief introduction of breast cancer.
Breast cancer is the most commonly diagnosed cancer in females.
The second is the second leading cause of cancer-related death
among women in the United States.
About 209,000 new cases were diagnosed
and about 40,000 cases of death occurred in the United States in 2010.
Normally we use mammography to detect breast cancer.
And mammography is a very effective detection tool
for the primary breast cancer.
However, it cannot detect the metastasis of the breast cancer.
And F18FDG, as I briefly mentioned,
is also the most commonly used PET imaging agent for the cancer detection,
including breast cancer.
So basically F18FDG can also be used for some other cancer detections.
And like I mentioned, F18FDG is not a cancer-specific agent.
So it has limited applications in detecting breast cancer metastasis
because of the lack of specificity.
And in this project, we're interested in using GRH receptors as targets
to develop imaging agents.
And because these GRH receptors are overexpressed on the breast cancer cells
as well as overexpressed on the human breast cancer samples,
and very importantly, the GRH peptides
can bind to the GRH receptors with nanobinding agents,
making it feasible to use peptides to specifically deliver imaging isotopes
for breast cancer imaging.
So as you can see here, this is a native GRH peptide sequence.
And both N-terminals and C-terminals are involved in the GRH receptor binding.
So if you want to attach a metal chelator to this molecule for radiolabeling,
basically you don't want to attach either N-terminals or C-terminals
because both are very important for the receptor binding.
So our hypothesis was the GRH peptide can specifically bind to the GRH receptors
on the human breast cancer cells,
and we can use it to deliver some diagnostic radionuclide,
specifically Indium-111, to breast cancer cells for breast cancer imaging here.
So as you can see, because both N-terminals and C-terminals
are involved in the receptor binding here,
therefore we choose to conjugate the radiomatter chelator here
through the de-lysine here, either through a linker.
As I mentioned, different linkers can be used,
either to optimize the binding affinity
as well as modify the bio-distribution properties of the whole molecule.
So first of all, to do the proof principle studies,
we designed three peptides to try to answer this question,
because the lysine has two amino groups,
an alpha-amino group and an epsilon-amino group.
So the first question when we tried to synthesize peptides was,
which group is better?
We don't know that.
Therefore, we kind of put the metal chelator through the linker,
either on the epsilon-amino group of de-lysine
or on the alpha-amino group of de-lysine.
And we also switched the de-lysine to L-lysine
to see if the configuration can also affect the binding affinity.
So essentially, by evaluating the three peptides,
we want to answer the question,
which amino group is the best in terms of the W-power group?
Here it shows you the peptide synthesis and the identification here.
Essentially, I'm not going to focus on the chemistry part here.
Essentially, we use F-mode chemistry to synthesize a peptide.
Here I'll just give you one example, which is DOTA,
A-H-X, D-lysine-16 and H-1.
So essentially, we conjugate the metal chelator DOTA
to the epsilon-amino group of de-lysine through the A-H-X linker here.
And after the peptide synthesis, we use HPLC to purify that
and also use mass spec to identify the peptide.
Then the next thing you want to do is,
the next question you want to answer is,
if the conjugation of the DOTA metal chelator
really affects the binding affinity of this molecule or not.
So essentially, we did a competition study here,
competitive assay study here.
And essentially, you can see three peptides
displayed different receptor binding affinity, essentially.
And the DOTA G and H-1, which was the link,
the metal chelator was conjugated to the epsilon-amino group
of de-lysine through the A-H-X linker,
displayed the highest receptor binding affinity here,
which was about 36.1 animal.
So essentially, through this in-vitro study,
we can conclude the conjugation of the DOTA
to epsilon-amino group of de-lysine,
maintain the nanomolar receptor,
G-H receptor binding affinity.
So after that, we'll just focus on that peptide
because it displayed 36.1 nanomolar binding affinity.
Here it shows you how to prepare indium-labeled compounds.
So you want to put a re-denucleotide to the peptide now
so essentially you can do spectra imaging.
The synthesis procedure is pretty straightforward.
Basically, you can put the peptide, re-denucleotide,
in a buffer and incubate it 75 to 45 minutes.
Then through the HPLC purification,
you get a very single peak here for the imaging.
And just to remind you,
the decay properties of the indium-O11,
indium-O11 is a good spectra imaging isotope.
It's being widely used in the clinic
in the nuclear medicine department.
And it has a 2.83 days half-life.
When indium-O11 decays, it can generate two gamma rays,
171 and 245 KeV gamma rays
that can be used for the imaging purpose.
And by the way, indium-O11 is commercially available,
so you can easily just order from Nordium
or like in Elma maybe to do your study.
Another important parameter we need to determine
is serum stability.
So you want to make sure the peptide you designed
is stable enough for them to find the receptor,
to bind to the receptor.
So here it shows you the stability of indium label
through the AHX, GnRH1 here.
This is a QC after the HPLC purification.
And this is two-hour serum stability data.
This is 18-hour serum stability data.
So pretty much, as you can see,
this peptide was stable in the mouse serum.
It's 37 degree up to 18 hours.
And we also want to show the specificity of this tracer
to bind to the GnRH receptor listed here.
So as you can see, without a peptide block,
with the peptide blockade, the binding to receptors,
GnRH receptor can be blocked by 85% here.
So if you put the code peptide to block the receptor sites,
then the binding drop down to about 15% of the original one.
Demonstrating this tracer,
even after you label it with indium-O11,
can still display GnRH receptor-specific binding.
Now, this slides shows you the GnRH receptor expression
on both cells and the xenografts.
So we choose MDA-MB231 human breast cancer cells
as cancer cells to generate animal models
to further evaluate the biodistribution properties
of the radio tracer.
So as you can see here,
GnRH receptors over-express both on the cells
and the tumor xenografts here,
making it a suitable model for us
to evaluate a tracer we develop.
This slides shows you the biodistribution
of this indium delta GnRH1 here.
And as you can see,
this tracer displays a very fast tumor update here.
0.5-hour post-injection,
it reached about 1.8% ID per gram in the tumor.
And to demonstrate possible,
we can use this one for the cancer imaging here.
Then we further determine the human breast cancer imaging
using the specs that you have
and use this probe to do the imaging studies.
And as you can see here,
we did this study with one-hour post-injection.
Basically, you inject the tracer into the mouse
through the tail vein,
and one-hour post-injection,
you put the mouse on the spec CT
to collect all these images.
So you can see the backbone of the mouse
collected by CT.
So it provides you the anatomic information
of the whole mouse.
And then all this colorful information is from a spec
and provides you the functional information of that tracer.
So essentially you can see,
by using this tracer you can clearly see
the MDN-B231 human breast cancer here.
And also you can see the urinary clearance here
as well as some kind of liver update here.
So this is two organs we're now working on
trying to decrease down the uptake
either in the kidney and liver.
So hopefully we can reach this conclusion.
The donor position display is an important factor
on the binding and feeding of the GIH peptide.
So essentially the coupling of the donor
to the epsilon immunogroup
is essential to remain the manual binding
and feeding of the GIH peptide.
And the successful imaging of this human breast cancer
xenograft tumor lesions using the imaging probe
we developed provide kind of a platform
for us to develop further more imaging probes
with improved bio-distribution properties.
Now let's switch gear to another type of cancer
which is melanoma.
In this type of cancer we are using different receptors.
So basically I'm going to give you the second example
by targeting G-protein cover receptors
you can use for cancer imaging.
A brief introduction on melanoma.
So melanoma is number six commonly diagnosed cancer
in the United States.
And one out of the 75 Americans
will eventually develop this disease during their lifetime.
And in fact one person dies in an hour in the United States
because of the malignant melanoma.
And about 68,000 new cases were diagnosed
and about 8,700 cases back-parked in the United States in 2010.
And we're very interested to develop an imaging agent
as well as a therapeutic agent for this cancer
because there's no curative treatment available
for metastatic melanoma.
And also melanoma specifically,
compared to other types of cancer,
is more resistant to the conventional chemotherapy agents.
We've been using melanoclonin-1, MC-1 receptors as targets
because this receptor overexpressed both human and mouse cells.
And as you can see, it's a G-protein cover receptor
with seven transmembrane domains here.
And very importantly, the alpha melanocytes
stimulating hormone peptide and many of its analogs
can bind to these receptors, like shown here,
as nanomolar or subnanomolar binding impurities.
Therefore, we're very interested in using the alpha MSH peptides
to deliver imaging isotope,
and eventually deliver therapeutic isotope
for melanoma treatment as well.
Let's look at the Y-type alpha MSH peptide.
So Y-type alpha MSH peptide is a peptide with 13 amino acids here,
and the amino acids impede our message sequence
for receptor binding.
So you have to keep these four amino acids there
for MC-1R binding as well in this same order.
It's very important.
And the NDP-MSH is a gold standard for in vitro binding studies
because this peptide has subnanomolar binding impurities
with the MC-1 receptors.
And several groups have tried to label this peptide,
linear peptide, with radionuclides for melanoma targeting.
And unfortunately, the success was limited
majorly because of the in vivo stability of linear peptide.
So one way to improve the in vivo stability of a peptide
is to cyclize the peptide.
So these slides give you an idea about different cyclizations
have a different effect in terms of tumor uptake
and kidney uptake here.
And the three peptides listed here,
the first one is Theta-CC-MSH.
So you can see this peptide is a linear peptide.
The second one is Theta-C-MSH.
The peptide was cyclized by the disulfide binding here.
And essentially, the third one is a metacyclized peptide.
Now, if you look at the bio-distribution data
at two-hour post-injection,
you can see the linear peptide displayed
moderate tumor uptake here,
about 5.9% per gram at two-hour post-injection.
And the kidney uptake was high,
about 63% high deeper gram at two-hour post-injection.
Now, when you switch to the disulfide-binding cyclized peptide,
which is peptide two,
the tumor uptake was slightly higher,
better than the first one, linear one.
Very important, if you look at the kidney,
you can see the kidney uptake dropped almost 50%,
45% probably.
And essentially, the medium cyclized peptide
displayed the best, the highest tumor uptake.
Here, it's about 17.3% high deeper gram.
And very importantly, you see the kidney uptake
further dropped to 8.7%.
So these two studies demonstrating
you can use peptide cyclization to improve the tumor uptake
and also affect the normal accumulation
of the tracer to the normal organs.
And also, different cyclizing strategy
has different effect in terms of the tumor uptake
and the renal uptake here.
So in my lab, I'm very interested about
using lactam bridge to cyclize the peptide.
The reason for that is metal cyclization
displayed very high tumor uptake,
but the synthesis is a little complicated.
You need to put a metal in it after the peptide synthesis.
Alternatively, if you use lactam bridge cyclization,
you can finish this cyclization easily
during the peptide synthesis.
So specifically, the first generation,
we're more focused on designing the peptide like this,
more close to the structure of native peptide,
alpha MSH peptide.
You can see we captured the MC1 binding sequence here
and the peptide was cyclized by a lysine aspect,
lactam bridge here.
And the dota is a good metal chelator,
so we conjugated dota to the peptide
either through a linker or without a linker.
So when you compare the biodistribution
of these two molecules, you can see the effect
of the linker on tumor uptake and also normal organ updates.
And the third one, we were interested in
if the dota position can really affect
the binding of tumor uptake or renal uptake as well.
So we conjugated the dota here instead of this side.
And also, you can label this peptide with Indian model map.
Okay.
Now, to evaluate the exact biodistribution properties
of the radio tracer, we specifically
established two models.
This is one of the models, D60F1,
the normal mouse model.
Essentially, this model is designed
to mimic the primary melanoma development.
So what we did was we inject a million D60F1 cells
subcutaneously in the right flank of the mouse.
And after 9 to 10 days, the tumor
will reach about 0.2 grams here.
And then you can use for biodistribution
or you can use for imaging studies.
Okay.
Now, here shows you the biodistribution
of melanoma imaging with this Indian dota,
gly-WCYC-MSH.
As you can see, this peptide has very high tumor uptake.
It's very high MC1 binding affinity,
about 0.9 nanomolar here.
And you can easily see the tumor lesions
can be easily visualized here using this tracer
as imaging probe by spec-CT images here.
So here is the kidneys and here is the bladder.
So you can easily see the urinary excretion pathway
of this peptide.
So specifically, just to remind you,
we have a full biodistribution published in this paper.
Just extract the information from that paper.
The tumor uptake was about 10.4% ID per gram,
two-hour post-injection.
And renal uptake was about 13.1% ID per gram,
a two-hour post-injection.
So this study demonstrated lactam-Bridge cyclation
also worked.
It works.
It can be used to cyclize a peptide
for good melanoma imaging.
So I didn't include the other peptide,
which was Indian dota CYC-MSH without linker.
So essentially, this peptide with the linker
has a little higher tumor uptake compared to that one.
And the kidney uptake was less than the peptide
without linker.
Here shows you the other peptide.
We conjugate data at a different position here.
And also, the binding affinity was high, 0.6 nanomolar.
And you can easily see the tumor lesions here as well
by using this imaging code for SPECT-CT images here.
And specifically, if you look at tumor uptake,
it was a little slightly higher, but comparable,
11.4% ID per gram, a two-hour post-injection.
And surprisingly, we had a very high kidney uptake here
compared to the previous one we talked.
It was about 60.5% ID per gram.
So essentially, even what I'm going to,
the taking-home message is even you have
a very similar binding affinity,
you can't really use imaging data to predict
what's a tumor uptake or the normal organ accumulation
will be.
So the bio-distribution study is necessary.
So now you may ask me a question.
Can you do some other, can you label the peptide
with some other imaging isotope?
The answer is yes.
So this gives you an example.
Basically, we can switch Indium-111 to gadium-67,
which is also a SPECT imaging isotope here.
So also, by switching Indium-111 to gadium-67,
this peptide also displayed a good tumor uptake here,
about 12.9% ID per gram, a two-hour post-injection.
You can easily see tumor lesions clearly here.
But compared to the Indium compound we just talked about,
the kidney uptake was a little higher.
So it's about 27.6 ID per gram, a two-hour post-injection.
And another potential application for this study is
you can easily switch this gadium-67 to gadium-68,
which is a generator-produced PET isotope for the PET imaging.
Okay, I mentioned we established two models.
So another model is P16F10, metastatic melanoma model,
trying to mimic the metastasis development in humans.
What we did is we inject these melanoma cells
into a mouse through the tail vein,
try to mimic the cancer cells detached from the primary site,
not get into the bloodstream, through the blood circulation,
try to establish metastasis in some other organs.
So essentially, because we inject into the tail veins,
the blood will pump back to the heart, then pump it out,
and actually the lung will be the first organ
to develop the metastasis.
But as time goes on, if time is long enough,
you can still see metastasis either in the bone, liver,
adrenal gland, and some other organs.
So here shows you the left panel,
shows you the CT image of a normal mouse.
And after the CT image, we took out the lung here.
So here shows you a proxy picture of a normal lung here.
And the right side shows you a CT image
of a mouse-bearing lung metastasis.
And this is the lung we took out after the CT image.
So if you look at the CT image, you can see for the normal mouse,
the lung was functional, 100% functional.
You see a lot of air in the lung area, dark area here.
But, you know, for this mouse-bearing lung metastasis,
the lung function was not 100%.
So you see some of the lungs still working,
but most of them didn't work.
You don't see a lot of air in the lung area.
So in other words, you can use micro-CT
to monitor the development of the metastasis.
Okay, now, so to answer the question,
if we can use imaging probe to detect metastasis,
we need to study with our imaging probe.
And meanwhile, we try to answer the question,
how good it is compared to FADG.
So essentially, we inject melanoma-bearing mouse
with the FADG first.
First day, we inject it in,
and then we collect the PET imaging of this mouse.
After study, we took the mouse and put it back in the cage,
waiting for another day.
So the reason for that is we try to wait the FADG decay.
So half-life for FADG is two hours.
So after a day, it decayed away.
And then we took the same mouse back
and injected with the idiom probe we developed here
and used SPECT imaging to collect the SPECT imaging
and then compared to see how easy or hard
we can find the metastasis.
So as you can see, you can see the accumulation
of the activity in the lung area by the FADG image,
but you cannot easily see the individual spots
developed here.
On the other hand, the SPECT imaging
using the idiom probe we developed,
you can easily see all the spots developing in the lung,
the melanoma metastasis here.
So indicating in the small animal model
and our receptor imaging probe is better than FADG
to pick up all the small metastasis developing in the lung.
And another study we also conducted was
we tried to compare two animals bearing metastatic melanoma
to see if we can use it to monitor the development.
So essentially, this mouse was 20 days post-cell injection here.
As you can see, as time goes on,
you have more metastasis develop here.
Also, the lesion kind of became bigger here.
In other words, what we tried to demonstrate
is if you start a chemotherapy or some other therapy treatment
here, sorry about that.
So if you start a treatment, then you
can use this imaging probe to monitor the therapeutic response
to see the shrinkage of the lesions.
And then we further did a study to try
to answer how early we can use this imaging probe
to detect metastasis.
So I've shown you the 17 days development and 20 days
development.
This study we did was 13 days post-IV injection.
So you can see there were only five individual spots
in the lung.
And by using the imaging probe, we can also clearly detect
this metastasis here.
And this is F18 PET imaging at 16 days post-development.
OK, let me talk about the second generation
of the lactobacillus cyclized peptide
for melanoma imaging.
So if you still remember the bio-distribution I showed
in the early slides, one question
we have after we kind of developed
the first generation peptide was the tumor uptake
for this peptide was not as high as the metacyclized peptide.
So the metacyclized peptide displayed 17.3% ID program
12 post-injection.
And the tumor uptake for the first generation peptide
is about 10.4%.
So one question was, we have demonstrated lactam bridge
cyclization work.
You can still develop this type of peptide
for melanoma targeting.
But the question was, can it be as good as metacyclized
or can it exceed the metacyclized peptide?
So we just simply looked at the structure
and said, OK, the direct difference
is the cyclization.
The cyclic moiety is different.
So for this one, we have 12 amino acid in this moiety.
In the metacyclized, we only have eight.
So I said, why don't we just try a smaller one?
We don't know if the size is an important factor
at that time.
And what we can do is just cyclize.
We just kept the MC1 binding sequence here.
But how about just cyclizing directly
using this ASP less lactam bridge?
So that's what we did.
But we were not sure if this is good or not.
But after the in vitro binding assay, we said, OK, it's good.
We're worried about this kind of cyclization
may affect the binding region very badly.
So after we got the binding affinity here, oh, it's still
good.
1.8 nanomolar binding affinity is still
kind of a very high binding affinity.
So this is the peptide I just talked about.
And meanwhile, we tried to use different type of linkers
to answer two questions.
The first is, we don't know if the NLE moiety, NLE
cyclic moiety is very important or not.
Can we insert amino acid in it to modify the biodistribution
properties?
Or we have to insert amino acid between delta and the NLE
instead of this between NLE and the cyclic moiety.
So we synthesized two peptide and determined IC50.
It was interesting to see.
Actually, it's not a good idea to insert amino acid linkers
here to separate NLE and the cyclic moiety.
Because if you did that, the binding affinity
dropped to 873 nanomolar.
But if you move the amino acid linker more towards the delta,
then the binding affinity comes back at 11.5 nanomolar.
And also, we did this peptide.
If you change this blue amino acid to glycine,
the binding affinity comes back around 2.1 nanomolar,
very close to this peptide without any linker.
Therefore, we decided, OK, let's do the biodistribution
for those two peptides to see.
So here shows you the biodistribution and imaging
of this indium delta NLECYCMSHX.
So basically, we don't have any more amino acid linker here.
After we saw the biodistribution, we were thrilled.
Because if you look at the tumor uptake, now it's 19.4%.
I need to grab 12 holes in here.
Even slightly higher than the metacycline.
So it seems like the smaller ring kind of works better
compared to the bigger ring in terms of the tumor targeting.
And importantly, if you look at the kidney uptake,
now dropped to 9.5%.
So in other words, it increased the tumor uptake,
also decreased down the ring uptake.
And now you can see from the image,
the contrast is better than the first-generation peptide here.
And you can easily see the lesion, flank lesion,
clearly here, OK?
If you look at the tumor-to-kidney uptake ratio
and compare with the metacyclized peptide
in the first generation, you can better understand
the improvement by switching to the second-generation peptide here.
So the blue columns are Indium-DOTA,
glycolysis, which was first-generation.
And this green columns are metacyclized peptide.
Yellow columns are second-generation peptide.
So essentially, you can see by switching to this
second-generation peptide, it displayed
a comparable high tumor-to-kidney uptake ratio
compared to the metacyclized,
very comparable with metacyclized peptide.
So here's you see the bio-distribution of the other peptide
with the GG-linker,
with the similar binding affinity, 2.1 nanomolar.
And you can see the tumor uptake was high as well,
so about 18.5% ideal gram per 2-hour post-injection.
Very importantly, all this normal organ accumulation
were lower than 1.5%, I would say.
And importantly, you see the kidney uptake now is about 7.5%,
so even further lower than the peptide
without the glycolytic linker.
And you can easily see the melanoma lesions clearly
with all these individual spots here.
A lot more information.
So this slide shows you the comparison
in kidney and liver uptake
between the peptide with GG-linker or without GG-linker.
So basically, the blue curves
are Indian peptide with the GG-linker in it.
So quickly, you can see by insert this GG-linker,
it decreased down the renal uptake about one-third, 30%,
and the liver uptake was decreased about two-thirds, 60%.
Now, if you look at the tumor-to-kidney ratio,
tumor-to-liver uptake ratio,
it's another way to really see the improvement.
So by insert a Gly-Gly-linker,
you kind of increase the tumor-to-kidney uptake ratio
as well as tumor-to-liver uptake ratio here.
So this is very important
because one of the directions we want to work with this peptide
is try to use the peptide to do the treatment.
So you can easily switch diagnostic,
radionuclide to therapeutic radionuclide.
For the therapeutic perspective,
then the ratio is important.
You want to deliver the maximum dose to the tumor
and the minimum dose to the normal organs, right?
So the improvement in tumor-to-kidney ratio
and tumor-to-liver ratio were significant.
So in conclusion,
so we have developed two generations
of the MC1-reservatory peptides.
Both primary and metastatic lesions
will be visualized by the first-generation peptide.
And I didn't show you the peptide distribution
of the peptide without linker,
but basically increasing the overall negative charge
of the peptide could significantly reduce
the renal uptake of the peptide
without affecting the tumor uptake.
And we found the reduction of the peptide size
essentially contributed to the tumor uptake,
increased the melanoma uptake of the second-generation peptide,
also decreased down the renal uptake.
Amino acid linkers exhibited profound effects.
So if you look at the peptide with the glycolytic linker
or without glycolytic linker,
you can easily see by inserting the amino acid linker
you can further decrease down the renal uptake
as well as the renal uptake.
So I'd like to thank the postdocs and graduate students
working in my lab and the collaborators in our cancer center
and the financial support to this project.
And I'd like to thank you for your attention.
I'd be happy to answer any questions.
Yes?
Can you mention that you could just take an image
and then have pins decay and then keep injecting
on different images?
Is there no, like, negative side effect
of having these two effects?
So, yeah, talking about the study we did
with the F18-FDG and the E-gamma micropeptides.
So one thing I'd like to get your attention is F18-FDG,
the targeting mechanism is different
with the peptide we injected.
So F18-FDG is not targeting the MC1 receptor, okay?
So basically the elevated uptake is because cancer cells
have higher antigen production compared to normal cells.
And the peptide we developed there is targeting the MC1R.
So I assume there's no cross-effects
between those two agents.
So another thing is if you want to do the dynamic image
over days, you can select, you know,
the imaging nucleotide diagnostic nucleotide
with longer half-life.
So you can, for example, even this Indian peptide,
you should be able to do it.
Half-life is about three days.
So I'm sure you can do, you know, 24 hours post-injection.
Same mouse, if you inject this probe,
either one of our 12-inch image,
and then you can put it back.
The only downside is if the peptide is too quickly
in the body, then you're going to lose activity.
Or you can inject a little more to make it last longer.
Yes?
I'm minimizing the kidney uptake,
so the signal will be lower.
Have you ever gotten to the point where the signal is low enough
that if, like, the tumor metastasizes, like,
to around the kidney or near the kidney,
can you distinguish, like, tumor just from, like,
kidney signal?
That's a good question.
Actually, in this case, because of peptide size,
so the excretion pathway is through the urinary system
to the kidney.
The kidney uptake was not receptor-mediated.
We have done a blocking study to show
it can block the tumor uptake,
but it cannot block the renal uptake.
So it's not specific.
So in terms if you have some metastasis in the kidney,
in this case, I don't think we can use this agent
to differentiate that, because the high,
you know, very, kind of a high uptake in the kidney.
The reason we want to reduce down the kidney uptake
is more focused on the therapeutic structure.
So in this case, if you switch to therapeutic reading,
you might want to deliver a maximum dose to the tumor
or less dose to the kidneys to avoid toxicity.
So just to follow up, the kidney uptake you say
is not specific, but it maintains in the kidney
longer than the tumor.
Is the keeling working?
There are several factors that affect the keeling.
First of all, it's not the MC1 receptor-mediated,
and the charge has been a major factor
contributing to the kidney uptake.
So for example, in this case, if we inject some
positive-structure amino acid, like lysine or arginine,
it can block the renal uptake up to 75% on the basis.
And also, recently, some of the paper published
talked about some of the, also,
receptor-mediated body with a broad spectrum.
So we didn't know exactly how this MC1,
this peptide kind of interacted.
You think it may be some receptor-mediated process,
but not the...
Not the MC1R receptor-mediated process, yeah.
Charge is a major factor, so normally we use charge to,
we use positive charge amino acid to block.
You can successively block up to 70% of the uptake.
So when you've got lower kidney uptake,
what should you see?
So actually, most of the activity in the kidney
are on the cortex area, not the inside.
So I think for that, it's just maybe charging the grafts.
So the positive charge for the peptide side
can interact with the negative charge of the kidney cells.
Yes?
The structure of your region, your lung region,
does it affect the stability of the immune system?
No.
No?
They're very stable.
Yeah, so what happens is for the linear peptide,
like an NDP peptide, you can label with the DOTA.
We put the DOTA there and label with Indian 0.11.
And what happens is enzyme can kind of find the amino acid
and chop it up.
So the peptide itself don't have enough time to deliver.
That's why you have the D times.
Yes.
Another way, I didn't mention, you know,
cycloaddition is one way, but you can switch
from natural amino acid to D amino acid.
It can also help increase amoeba inseparability.
Because when you switch from L configuration to D configuration,
enzyme has a hard time to really recognize that
and chop the peptide.
Yes?
I would like to go back to the study where you compared
the PET and SPECT image of the pulmonary metastasis.
And you suggested that the SPECT was echoes,
and the SPECT there are the metastatic cells, right?
So did you try to really have a radiography of that
just to make sure that it's really what you're observing?
Because, you know, from my experience,
the SPECT image very often that you're doing
in this direction produces the SPECTs,
which are nothing real.
They're just some archetypes.
We did that study.
So we used our radiography as well as we take the lung out,
put it on a piece of paper,
lie it out, and do the SPECT imaging for that as well.
So we drew that image on the paper,
identify all these spots.
We did that as well, on the radiography,
and on the SPECT as well.
And the second question which I had was,
the first study would be another problem
with the receptor.
So you showed that the SPECT image,
but also those receptors are expressed in the breast
and lymphocytes on the prostate and also on the ovaries.
And I didn't see those actually organs.
Is that true?
You're right.
So this GIH receptor not only just overexpress
breast cancer cells, also prostate cancer.
The mice we used, first of all, we used the female mice.
And so...
In the ovaries.
Yes, you're right.
But from image, we didn't see the update.
But unfortunately, we didn't really take out the ovaries
to count.
So from virus prediction, we should be able to see that.
But we didn't do that study at that time.
I think it's the question of the complexity.
Might be.
Is it what the expression levels are?
Yeah, maybe the...
Yes, John, that's a good point.
The expression level may be different as well.
But we haven't really focused on ovarian cancer yet.
But it's been reported.
I think one of the cell lines
was used for the...
This OVA3 could be used for this GIH receptor
and reported the expression.
But the level, I don't have the detailed data about it
compared to this.
Is that cancer cells over there?
Yeah.
One moment.
When you switch from immune to guide,
what should decrease the kidney outbreak?
Increase.
Increase the...
So it's not an issue in the chelate step?
Because immune and guide...
Normally, when we switch isotopes,
sometimes you don't see any difference
in terms of renal update or kidney update.
But sometimes you do see either in the tumor update
or the kidney update.
We don't know exactly the reason.
The coordination chemistry is a little different, though.
May contribute to this.
Because the copper chelation of the...
Not this one.
So DOTA is a very good chelator for indium and the guide.
Very good chelator.
In terms of a copper-64 dimension,
specifically, DOTA is not an optimal chelator for copper-64.
The reason for that is once it gets in the bloodstream,
some of the enzymes will compete with the copper-64.
So that's why...
I don't know if you've been to my first talk.
We talked about the copper-64 with DOTA and with NODA.
And you can see some of the very high
normal organ accumulations there.
That's because some of the enzymes
are coordinated with the copper-64.
But when you switch to NODA, it's very stable.
That case is very stable.
And then, easily, through the biospecial comparison,
you can see there's no...
You know, the normal organ accumulation
are very, very low.
Less than 1% in that case.
But for the indium and the gallium,
DOTA has been a very good chelator for both.
Any more questions?
All right.

